An Open-Label, Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia (FTD)
NCT05483322 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2022-08-02
Summary
This is an open-label, single subject, expanded access protocol (EAP) of the LAM-002A investigational product administered orally at 125 mg BID for 52 weeks.
Conditions
- Frontotemporal Dementia
Interventions
- DRUG
-
LAM-002A
25mg capsules
Sponsors & Collaborators
-
OrphAI Therapeutics
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration
NCT00187525 ·Status: COMPLETED ·Phase: PHASE4
-
Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia
NCT00594737 ·Status: COMPLETED ·Phase: PHASE3
-
Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD)
NCT00127114 ·Status: WITHDRAWN ·Phase: PHASE4
-
Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients
NCT00200538 ·Status: COMPLETED ·Phase: PHASE2
-
Longitudinal Study of Brain Amyloid imaGing in MEMENTO
NCT02164643 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease
NCT01864655 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease
NCT00359944 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Pharmacodynamic Effects of Single Oral Doses of PF-06648671 on β-Amyloid (Aβ) Concentrations in Cerebrospinal Fluid (CSF)
NCT02407353 ·Status: COMPLETED ·Phase: PHASE1
-
A Study To Examine The Distribution Of PF-05212377 In The Brain Of Healthy Volunteer Subjects Using Positron Emission Tomography And A Radioactive Tracer Following Oral Administration Of One Dose Of PF-05212377
NCT02005991 ·Status: COMPLETED ·Phase: PHASE1
-
Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease
NCT03703856 ·Status: COMPLETED ·Phase: PHASE4
-
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
NCT05522387 ·Status: TERMINATED ·Phase: PHASE2
-
Exploratory and Safety Study of [F-18]W372
NCT00954369 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Evaluation of [18F]RO6958948 as Tracer for Positron Emission Tomography (PET) Imaging of Tau Burden in Alzheimer's Disease Participants
NCT02792179 ·Status: COMPLETED ·Phase: PHASE1
-
Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease
NCT01028053 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)
NCT03987295 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease
NCT00933608 ·Status: COMPLETED ·Phase: PHASE4
-
Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD
NCT03819699 ·Status: TERMINATED ·Phase: PHASE1
-
Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers
NCT01005862 ·Status: COMPLETED ·Phase: PHASE1
-
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
NCT03748706 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease
NCT00566397 ·Status: COMPLETED ·Phase: PHASE2
-
Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease
NCT04994483 ·Status: COMPLETED ·Phase: PHASE3
-
Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients
NCT04388254 ·Status: COMPLETED ·Phase: PHASE2
-
Dopaminergic Therapy for Frontotemporal Dementia Patients
NCT04937452 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease
NCT00469456 ·Status: COMPLETED ·Phase: PHASE4
-
"Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies"
NCT01023672 ·Status: COMPLETED ·Phase: PHASE4